Department of Neurological Surgery, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.
Cancer. 2012 Feb 15;118(4):1048-54. doi: 10.1002/cncr.26362. Epub 2011 Jul 19.
A study was undertaken to define the variables associated with tumor control and survival after single-session stereotactic radiosurgery (SRS) for patients with atypical and malignant intracranial meningiomas.
Fifty patients with World Health Organization (WHO) grade II (n = 37) or grade III (n = 13) meningiomas underwent SRS from 1990 to 2008. Most tumors were located in the falx/parasagittal region or cerebral convexities (n = 35, 70%). Twenty patients (40%) had progressing tumors despite prior external beam radiation therapy (EBRT) (median dose, 54.0 grays [Gy]). The median treatment volume was 14.6 cm(3) ; the median tumor margin dose was 15.0 Gy. Seven patients (14%) received concurrent EBRT (median dose, 50.4 Gy). Follow-up (median, 38 months) was censored at last evaluation (n = 28) or death (n = 22).
Tumor grade correlated with disease-specific survival (DSS) (hazard ratio [HR], 3.4; P = .008), local tumor control (HR, 2.4; P = .02), and progression-free survival (PFS) (HR, 2.6; P = .02) on univariate analysis, but not on multivariate analysis. Multivariate analysis showed that having failed EBRT and tumor volume >14.6 cm(3) were negative predictors of DSS and local control (HR, 3.0; P = .02 and HR, 4.4; P = .01; HR, 3.3; P = .001 and HR, 2.3; P = .02;, respectively). Having failed EBRT was a negative predictor of PFS (HR, 3.5; P = .002). Thirteen patients (26%) had radiation-related complications at a median of 6 months after radiosurgery.
Tumor progression despite prior EBRT and larger tumor volume are negative predictors of tumor control and survival for patients having SRS for WHO grade II and III intracranial meningiomas.
本研究旨在确定单次立体定向放射外科(SRS)治疗非典型和恶性颅内脑膜瘤患者的肿瘤控制和生存相关变量。
1990 年至 2008 年期间,50 例世界卫生组织(WHO)分级 II 级(n=37)或 III 级(n=13)脑膜瘤患者接受 SRS 治疗。大多数肿瘤位于镰旁/矢状旁区或大脑凸面(n=35,70%)。20 例(40%)患者尽管先前接受过外照射放疗(EBRT)(中位剂量 54.0 戈瑞[Gy]),肿瘤仍在进展。中位治疗体积为 14.6cm3;肿瘤边缘剂量的中位数为 15.0Gy。7 例(14%)患者接受同步 EBRT(中位剂量 50.4Gy)。中位随访(38 个月)截止至最后一次评估(n=28)或死亡(n=22)。
肿瘤分级与疾病特异性生存(DSS)(风险比[HR],3.4;P=.008)、局部肿瘤控制(HR,2.4;P=.02)和无进展生存(PFS)(HR,2.6;P=.02)显著相关,单因素分析,但多因素分析无相关性。多因素分析显示,EBRT 失败和肿瘤体积>14.6cm3是 DSS 和局部控制的负预测因子(HR,3.0;P=.02 和 HR,4.4;P=.01;HR,3.3;P=.001 和 HR,2.3;P=.02)。EBRT 失败是 PFS 的负预测因子(HR,3.5;P=.002)。放射外科治疗后中位 6 个月时,有 13 例(26%)患者出现与放射治疗相关的并发症。
尽管先前接受过 EBRT 治疗且肿瘤体积较大的患者,其 SRS 治疗后肿瘤控制和生存情况较差,这是 WHO 分级 II 和 III 级颅内脑膜瘤患者的负预测因子。